Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Siebert, Stefan ^a   Porter, Duncan ^b   Paterson, Caron ^a   Hampson, Rosie ^b   Gaya, Daniel ^b   Latosinska, Agnieszka ^c   Mischak, Harald ^a,c   Schanstra, Joost ^d,e   Mullen, William ^a   McInnes, Iain ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^c Mosaiques Diagnostics   (Germany)

^d INSERM   (France)

^e UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PEPTIDE;

CASE CONTROL STUDY; DEMOGRAPHY; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; URINE;

ARTHRITIS, RHEUMATOID; BIOMARKERS; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PEPTIDES; PROTEOMICS; ROC CURVE;

EID: 85009727888     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40473     Document Type: Article

References (35)

1. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73(3), 492-509 (2014).
2. Nam, J. L. Rheumatoid arthritis management of early disease. Curr. Opin. Rheumatol. 28(3), 267-74 (2016).
3. Whiting, P. F. et al. Systematic review: Accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann. Intern. Med. 152(7), 456-64 (2010).
4. Schanstra, J. P. et al. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. J Am Soc. Nephrol. 26(8), 1999-2010 (2015).
5. Kuznetsova, T., Mischak, H., Mullen, W. & Staessen, J. A. Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur. Heart J 33(18), 2342-50 (2012).
6. Carty, D. M. et al. Urinary proteomics for prediction of preeclampsia. Hypertension 57(3), 561-9 (2011).
7. Delles, C. et al. Urinary proteomic diagnosis of coronary artery disease: Identification and clinical validation in 623 individuals. J. Hypertens. 28(11), 2316-22 (2010).
8. Schanstra, J. P. & Mischak, H. Proteomic urinary biomarker approach in renal disease: From discovery to implementation. Pediatr. Nephrol. 30(5), 713-25 (2014).
9. Klein, J., Bascands, J. L., Mischak, H. & Schanstra, J. P. The role of urinary peptidomics in kidney disease research. Kidney Int. 89(3), 539-45 (2016).
10. Mischak, H., Vlahou, A. & Ioannidis, J. P. Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience. Clin. Biochem. 46(6), 432-43 (2013).
11. Jantos-Siwy, J. et al. Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. J. Proteome. Res. 8(1), 268-81 (2009).
12. Pontillo, C. et al. CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clin Appl. 9(3-4), 322-34 (2015).
13. Stalmach, A. et al. Identification of urinary Peptide biomarkers associated with rheumatoid arthritis. PLoS One 9(8), e104625 (2014).
14. Dakna, M. et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC. Bioinformatics. 11, 594 (2010).
15. Liu, Y. Z. et al. RNA-sequencing study of peripheral blood monocytes in chronic periodontitis. Gene 581(2), 152-60 (2016).
16. Elsaid, K. A. & Chichester, C. O. Review: Collagen markers in early arthritic diseases. Clin. Chim. Acta 365(1-2), 68-77 (2006).
17. Fragiadaki, M. et al. High doses of TGF-beta potently suppress type I collagen via the transcription factor CUX1. Mol. Biol. Cell 22(11), 1836-44 (2011).
18. Hsueh, M. F., Onnerfjord, P. & Kraus, V. B. Biomarkers and proteomic analysis of osteoarthritis. Matrix Biol. 39, 56-66 (2014).
19. Butt, A. Q., McArdle, A., Gibson, D. S., FitzGerald, O. & Pennington, S. R. Psoriatic arthritis under a proteomic spotlight: Application of novel technologies to advance diagnosis and management. Curr. Rheumatol. Rep. 17(5), 35 (2015).
20. Park, Y. J., Chung, M. K., Hwang, D. & Kim, W. U. Proteomics in Rheumatoid Arthritis Research. Immune Netw. 15(4), 177-85 (2015).
21. Collins, E. S. et al. A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-Alpha treatment of psoriatic arthritis. Proteomics Clin Appl 10(6), 645-62 (2016).
22. Mischak, H. et al. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments. Mass Spectrom. Rev. 28(5), 703-24 (2009).
23. Mischak, H. et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl. 4(4), 464-78 (2010).
24. Kronisch, C. et al. Predicting functional disability: One year results from the Scottish Early Rheumatoid Arthritis Inception Cohort. Arthritis Rheumatol. 68(7), 1596-602 (2016).
25. Haubitz, M. et al. Identification and validation of urinary biomarkers for differential diagnosis and dvaluation of therapeutic intervention in ANCA associated vasculitis. Mol. Cell. Proteomics 8, 2296-307 (2009).
26. Stalmach, A., Albalat, A., Mullen, W. & Mischak, H. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis 34(11), 1452-64 (2013).
27. Neuhoff, N. et al. Mass spectrometry for the detection of differentially expressed proteins: A comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun. Mass Spectrom. 18(2), 149-56 (2004).
28. Nkuipou-Kenfack, E. et al. Identification of ageing-Associated naturally occurring peptides in human urine. Oncotarget. 6(33), 34106-17 (2015).
29. Lindhardt, M. et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): Essential study design and rationale of a randomised clinical multicentre trial. BMJ Open 6(3), e010310 (2016).
30. Siwy, J. et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol. Dial. Transplant 29(8), 1563-70 (2014).
31. Weissinger, E. M. et al. Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia 28(4), 842-52 (2014).
32. Klein, J., Papadopoulos, T., Mischak, H. & Mullen, W. Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis 35(7), 1060-4 (2014).
33. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B 57(1), 125-33 (1995).
34. Rouse, R. et al. Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat. PLoS One 7(4), e34606 (2012).
35. Woodcock, J. US Food and Drug Administration "Http://Www.Fda.Gov/Downloads/Drugs/DevelopmentApprovalProcess/UCM518268.Pdf," in (2016).